At Cincinnati Children’s, we make science count for kids.

Every day, more than 1,000 doctors, nurses, scientists, researchers and staff in our Cancer and Blood Diseases Institute work as focused teams to provide the most innovative care for the most difficult cancer cases in the world.

"We have the nation’s leading pediatric cancer experts with outstanding international reputations, but the key ingredient is team science,” says John Perentesis, MD, FAAP, director of Oncology and Cancer Programs and co-director of the Cancer and Blood Diseases Institute. “Each of our clinical teams is embedded with basic science researchers. This close collaboration allows advances from the laboratory to reach children as quickly as possible.”

This fall, Cincinnati Children’s is opening a new Proton Therapy and Research Center that will transform how children receive radiation therapy. This $120 million facility will become an integral part of our precision medicine center, which uses the latest in genomic science to design precise, individual treatments for children and young adults with cancer. The centerpiece of the facility is a $23 million particle therapy research unit dedicated to develop the newest and most advanced treatments for childhood cancers.

“We have the largest array of new anti-cancer treatments for children of any medical center in the country. As a result, children with very complex cases are referred here from all around the world,” Perentesis says.  “We are proud that Cincinnati Children’s has been ranked at the top of the ‘50 Most Amazing Children’s Hospitals in the World’, and the proton therapy and research center will put us at the forefront of this amazing new technology.”

Why we stand out:

  • Our cancer precision genomics-guided treatment program is one of the main reasons why so many children with high-risk or relapsed malignancies are referred here from all around the world. According to our latest research, about 50 percent of children with high-risk forms of cancer receiving genomics-guided treatment experienced dramatic tumor shrinkage compared to just 6 percent without genomic guidance. This new treatment approach helps to provide a path for curing chemotherapy-resistant relapsed cancers and leukemias.
  • Our new Proton Therapy Center will significantly improve outcomes while dramatically reducing potential long-term risks of radiation therapy. The facility will be one of only two pediatric-focused proton therapy centers in the U.S., and the only one on the globe with a fully dedicated proton research center.
  • We are the leading national center for bone marrow transplants and related engineered anti-cancer and leukemia immune cellular therapies.
  • We have developed a nationally leading innovative, multidisciplinary fertility preservation program for girls and boys undergoing cancer treatment that will help childhood cancer survivors become parents when they grow up.
  • We are a leader in developing anti-cancer immune therapies, including a new program that uses engineered T-cells against relapsed leukemias.
  • Scientists in our Brain Tumor Center are developing a breakthrough method to convert deadly high-grade gliomas into a much more treatable form of cancer. This research remains in very early stages, but in years to come this approach may provide much-improved outcomes for children with rare, difficult-to-treat tumors.

Learn more about our Cancer and Blood Diseases Institute